Seroquel (Quetiapine) Dosing

Schizophrenia

For adults with schizophrenia, initiate quetiapine at 25 mg twice daily on Day 1, then increase by 25-50 mg divided 2-3 times daily on Days 2-3 to reach 300-400 mg by Day 4, with a target therapeutic range of 150-750 mg/day (maximum 750 mg/day). 1

Standard Titration Schedule for Adults

Day 1: 25 mg twice daily 1
Day 2: Increase to total of 100 mg/day (divided doses) 1
Day 3: Increase to total of 200 mg/day (divided doses) 1
Day 4: Reach 300-400 mg/day (divided doses) 1
Maintenance: 150-750 mg/day, with most patients responding optimally at 300-450 mg/day 1, 2

Adolescents (13-17 years)

Day 1: 25 mg twice daily 1
Day 2: 100 mg/day total (divided twice daily) 1
Day 3: 200 mg/day total (divided twice daily) 1
Day 4: 300 mg/day total (divided twice daily) 1
Day 5: 400 mg/day total (divided twice daily) 1
Target range: 400-800 mg/day (maximum 800 mg/day) 1
Further adjustments should not exceed 100 mg/day increments and may be administered three times daily based on response 1

Evidence on Dose-Response

Fixed-dose studies demonstrate that 150-450 mg/day is more effective than placebo and equally effective as 600-750 mg/day 3
Pooled data support therapeutic efficacy at average doses of 254-525 mg/day, equivalent to standard doses of other antipsychotics 3
The balance of evidence does not support routine use of doses exceeding 800 mg/day, despite some case reports suggesting benefit at higher doses 3

Rapid Dose Escalation (Acute Settings)

In hospitalized patients with acute psychosis, quetiapine can be escalated to 400 mg/day in as little as 2-3 days with similar safety and tolerability as the standard 5-day schedule 4
This faster titration allows therapeutic response to be achieved more quickly when clinically necessary 4

Bipolar Disorder

Acute Mania (Adults)

For acute mania, initiate quetiapine at 100 mg/day total (divided twice daily) on Day 1, then escalate to 400 mg/day by Day 4, with a target range of 400-800 mg/day (maximum 800 mg/day). 1

Day 1: 100 mg/day total (divided twice daily) 1
Day 2: 200 mg/day total (divided twice daily) 1
Day 3: 300 mg/day total (divided twice daily) 1
Day 4: 400 mg/day total (divided twice daily) 1
Further increases up to 800 mg/day by Day 6 should not exceed 200 mg/day increments 1
Can be used as monotherapy or adjunct to lithium or divalproex 1

Acute Mania (Children and Adolescents 10-17 years)

Day 1: 25 mg twice daily 1
Day 2: 100 mg/day total (divided twice daily) 1
Day 3: 200 mg/day total (divided twice daily) 1
Day 4: 300 mg/day total (divided twice daily) 1
Day 5: 400 mg/day total (divided twice daily) 1
Target range: 400-600 mg/day (maximum 600 mg/day) 1
Further adjustments should not exceed 100 mg/day increments and may be administered three times daily 1

Bipolar Depression (Adults)

For bipolar depression, administer quetiapine once daily at bedtime, starting at 50 mg on Day 1 and escalating to the target dose of 300 mg/day by Day 4 (maximum 300 mg/day). 1, 5

Day 1: 50 mg at bedtime 1
Day 2: 100 mg at bedtime 1
Day 3: 200 mg at bedtime 1
Day 4: 300 mg at bedtime 1
Both 300 mg/day and 600 mg/day showed similar efficacy, with no advantage to higher dosing 5

Maintenance Therapy (Bipolar I Disorder)

Continue 400-800 mg/day (divided twice daily) as adjunct to lithium or divalproex 1
Generally maintain the same dose that successfully stabilized the acute episode 1
Quetiapine responders who continued therapy for up to 52 weeks had significantly reduced risk of mood event recurrence compared to placebo 5

Major Depressive Disorder

Quetiapine is not FDA-approved as monotherapy for major depressive disorder; its use in this indication is limited to bipolar depression as described above. 1

Special Populations

Elderly Patients

Start elderly patients at 50 mg/day and increase in 50 mg/day increments based on clinical response and tolerability, using a slower titration rate than younger adults. 1

Elderly patients have 20-30% higher plasma concentrations and up to 50% lower clearance compared to younger patients 2
Consider predisposition to hypotensive reactions when dosing 1

Hepatic Impairment

Initiate at 25 mg/day and increase daily in 25-50 mg/day increments to an effective dose. 1

Oral clearance is reduced by approximately 25% in patients with hepatic cirrhosis 2

Renal Impairment

Mean oral clearance is reduced by approximately 25% in severe renal impairment 2
Use caution and consider lower starting doses 1

Alzheimer's Disease with Behavioral Symptoms

For problematic delusions, hallucinations, or severe agitation in Alzheimer's disease, initiate quetiapine at 12.5 mg twice daily and titrate to a maximum of 200 mg twice daily. 6

Quetiapine is more sedating than other atypical antipsychotics, which can be beneficial for agitation 6
Beware of transient orthostatic hypotension, particularly in elderly patients 6

Critical Safety Considerations

Orthostatic Hypotension

Quetiapine commonly causes orthostatic hypotension, particularly during initial dose titration 6
Monitor blood pressure, especially in elderly patients and those with cardiovascular disease 6
Consider slower titration in patients at risk for hypotensive reactions 1

Weight Gain

Quetiapine is associated with weight gain averaging approximately 2.1 kg in short-term trials 2
Monitor body mass index monthly for 3 months, then quarterly 7
Obtain baseline and follow-up fasting glucose and lipid panels 7

Metabolic Effects

Some patients experience clinically relevant increases in blood glucose or lipid parameters 5
Baseline metabolic assessment should include BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid panel 7
Follow-up monitoring: blood pressure, glucose, and lipids at 3 months, then yearly 7

QTc Prolongation

Quetiapine is associated with minor ECG changes, but clinically significant QTc prolongation is uncommon 6
Monitor ECG in patients with cardiac risk factors 6

Hematological Monitoring

Although agranulocytosis is primarily associated with clozapine, it can occur with any antipsychotic 6
Consider baseline and periodic complete blood counts, particularly if symptoms of infection develop 6

Drug Interactions

Reduce quetiapine dose to one-sixth of the original dose when co-administered with potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nefazodone). 1

Quetiapine is extensively metabolized by CYP3A4 2
CYP3A4 inducers may require dose increases 2

Common Pitfalls to Avoid

Do not exceed 750 mg/day in adults with schizophrenia or 800 mg/day in bipolar disorder without clear clinical justification, as evidence does not support routine high-dose use 1, 3
Do not titrate too rapidly in elderly patients, as they are more susceptible to orthostatic hypotension and sedation 6, 1
Do not ignore metabolic monitoring, particularly weight gain and glucose/lipid abnormalities, which can significantly impact long-term morbidity 7, 5
Do not abruptly discontinue quetiapine in patients on maintenance therapy, as this may precipitate relapse 8
Do not use quetiapine as monotherapy for unipolar major depressive disorder, as it is not FDA-approved for this indication 1

What is the recommended dosing regimen for Seroquel (quetiapine) in patients with schizophrenia, bipolar disorder, or major depressive disorder, considering factors such as age, medical history, and potential side effects like orthostatic hypotension and weight gain?

Help us tailor your experience